The global cell and gene therapy manufacturing market, valued at USD 14.69 billion in 2025, is projected to reach USD 122.86 billion by 2034, growing at a CAGR of 26.62%. The market is driven by advances in manufacturing processes and the rising prevalence of chronic diseases, with North America holding the largest share.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Manufacturing Market, by Therapy
8.1.1. Cell Therapy Manufacturing
8.1.1.1. Market Revenue and Forecast
8.1.2. Gene Therapy Manufacturing
8.1.2.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy Manufacturing Market, by Scale
9.1.1. Pre-commercial/ R&D Scale Manufacturing
9.1.1.1. Market Revenue and Forecast
9.1.2. Commercial Scale Manufacturing
9.1.2.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy Manufacturing Market, by Mode
10.1.1. Contract Manufacturing
10.1.1.1. Market Revenue and Forecast
10.1.2. In-house Manufacturing
10.1.2.1. Market Revenue and Forecast
11.1. Cell and Gene Therapy Manufacturing Market, by Workflow
11.1.1. Cell Processing
11.1.1.1. Market Revenue and Forecast
11.1.2. Cell Banking
11.1.2.1. Market Revenue and Forecast
11.1.3. Process Development
11.1.3.1. Market Revenue and Forecast
11.1.4. Fill & Finish Operations
11.1.4.1. Market Revenue and Forecast
11.1.5. Analytical & Quality Testing
11.1.5.1. Market Revenue and Forecast
11.1.6. Raw Material Testing
11.1.6.1. Market Revenue and Forecast
11.1.7. Vector Production
11.1.7.1. Market Revenue and Forecast
11.1.8. Others
11.1.8.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy
12.1.2. Market Revenue and Forecast, by Scale
12.1.3. Market Revenue and Forecast, by Mode
12.1.4. Market Revenue and Forecast, by Workflow
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy
12.1.5.2. Market Revenue and Forecast, by Scale
12.1.5.3. Market Revenue and Forecast, by Mode
12.1.5.4. Market Revenue and Forecast, by Workflow
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy
12.1.6.2. Market Revenue and Forecast, by Scale
12.1.6.3. Market Revenue and Forecast, by Mode
12.1.6.4. Market Revenue and Forecast, by Workflow
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy
12.2.2. Market Revenue and Forecast, by Scale
12.2.3. Market Revenue and Forecast, by Mode
12.2.4. Market Revenue and Forecast, by Workflow
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy
12.2.5.2. Market Revenue and Forecast, by Scale
12.2.5.3. Market Revenue and Forecast, by Mode
12.2.5.4. Market Revenue and Forecast, by Workflow
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy
12.2.6.2. Market Revenue and Forecast, by Scale
12.2.6.3. Market Revenue and Forecast, by Mode
12.2.6.4. Market Revenue and Forecast, by Workflow
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy
12.2.7.2. Market Revenue and Forecast, by Scale
12.2.7.3. Market Revenue and Forecast, by Mode
12.2.7.4. Market Revenue and Forecast, by Workflow
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy
12.2.8.2. Market Revenue and Forecast, by Scale
12.2.8.3. Market Revenue and Forecast, by Mode
12.2.8.4. Market Revenue and Forecast, by Workflow
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy
12.3.2. Market Revenue and Forecast, by Scale
12.3.3. Market Revenue and Forecast, by Mode
12.3.4. Market Revenue and Forecast, by Workflow
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy
12.3.5.2. Market Revenue and Forecast, by Scale
12.3.5.3. Market Revenue and Forecast, by Mode
12.3.5.4. Market Revenue and Forecast, by Workflow
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy
12.3.6.2. Market Revenue and Forecast, by Scale
12.3.6.3. Market Revenue and Forecast, by Mode
12.3.6.4. Market Revenue and Forecast, by Workflow
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy
12.3.7.2. Market Revenue and Forecast, by Scale
12.3.7.3. Market Revenue and Forecast, by Mode
12.3.7.4. Market Revenue and Forecast, by Workflow
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy
12.3.8.2. Market Revenue and Forecast, by Scale
12.3.8.3. Market Revenue and Forecast, by Mode
12.3.8.4. Market Revenue and Forecast, by Workflow
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy
12.4.2. Market Revenue and Forecast, by Scale
12.4.3. Market Revenue and Forecast, by Mode
12.4.4. Market Revenue and Forecast, by Workflow
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy
12.4.5.2. Market Revenue and Forecast, by Scale
12.4.5.3. Market Revenue and Forecast, by Mode
12.4.5.4. Market Revenue and Forecast, by Workflow
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy
12.4.6.2. Market Revenue and Forecast, by Scale
12.4.6.3. Market Revenue and Forecast, by Mode
12.4.6.4. Market Revenue and Forecast, by Workflow
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy
12.4.7.2. Market Revenue and Forecast, by Scale
12.4.7.3. Market Revenue and Forecast, by Mode
12.4.7.4. Market Revenue and Forecast, by Workflow
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy
12.4.8.2. Market Revenue and Forecast, by Scale
12.4.8.3. Market Revenue and Forecast, by Mode
12.4.8.4. Market Revenue and Forecast, by Workflow
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy
12.5.2. Market Revenue and Forecast, by Scale
12.5.3. Market Revenue and Forecast, by Mode
12.5.4. Market Revenue and Forecast, by Workflow
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy
12.5.5.2. Market Revenue and Forecast, by Scale
12.5.5.3. Market Revenue and Forecast, by Mode
12.5.5.4. Market Revenue and Forecast, by Workflow
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy
12.5.6.2. Market Revenue and Forecast, by Scale
12.5.6.3. Market Revenue and Forecast, by Mode
12.5.6.4. Market Revenue and Forecast, by Workflow
13.1. Wuxi Advanced Therapies
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck KGaA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fischer Scientific
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Miltenyi Biotec
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Takara Bio Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bluebird Bio Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Hitachi Chemical Co., Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cellular Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description